This review focuses on management of GIST with KIT and PDGFRA mutations. Imatinib is first-line treatment for unresectable gastrointestinal stromal tumors (GISTs) unless they harbor a PDGFRA D842V mutation; it is recommended to escalate imatinib to twice daily dosing for KIT exon 9 mutant tumors....
Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA. Gastroenterology 2006;131:1907–1912. Article CAS PubMed Google Scholar Kang DY, Park CK, Choi JS et al. Multiple gastrointestinal stromal tumors: clinicopathologic and genetic ...
Conclusion: Sarcomatosis is most commonly seen ingastrointestinal stromal tumor gastrointestinal stromal tumor Abstract. Malignant gastrointestinal stromal tumor (GIST) isa rare type of sarcoma that is found in the digestive system, most often in the wall of the stomach. Multiple GISTs are extremely ...
GISTGastrointestinal Stromal Tumor GISTGwangju Institute of Science and Technology(Korea) GISTGeneralized Search Trees GISTGeneral Internet Signaling Transport GISTGeneralized Search Tree GISTGeographic Information Support Team(community of interest of humanitarian geospatial experts) ...
KAREN BERGER, PHARMD, is a pharmacist at an independent pharmacy in northern New Jersey. REFERENCES What are gastrointestinal stromal tumors? American Cancer Society. Updated December 1, 2019. Accessed July 12, 2020. https://www.cancer.org/cancer/gastrointestinal-stromal-tumor/about/what-is-gist....
AML, acute myeloid leukemia; CLL, chronic lymphocytic leukaemia; CRC, colorectal cancer; CRPC, castration-resistant prostate cancer; CTLA-4, cytotoxic T-lymphocyte antigen-4; GIST, gastrointestinal stromal tumour; HCC, hepatic cell carcinoma; LAG-3, lymphocyte activation gene 3; mAb, monoclonal ...
Imatinib is a potent tyrosine kinase inhibitor, which is mainly used in the treatment of chronic myelogenous leukemia (CML) and is also effective in patients with gastrointestinal stromal tumor (GIST). Although most cases of imatinib-induced pulmonary adverse events have been reported in patients wit...
Understanding Gastric GIST: From Pathophysiology to Personalized Treatment Background: Gastric gastrointestinal stromal tumors (GISTs) represent a subset of gastrointestinal tumors predominantly found in the stomach. Despite their... DFC Moga,G Vldoiu,AM Fril,... - 《Journal of Clinical Medicine》 被...
Antonio Ucar, MD, explains the rationale behind the phase 3 Peak study of bezuclastinib plus sunitinib in patients with gastrointestinal stromal tumors being treated in the second-line setting. Antonio Ucar, MD, an oncologist/hematologist at Miami Canc...
To date, this compound has been approved for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), RCC and P-NETs [14,97,98]. The EMA in 2010 and the FDA in 2011 approved sunitinib for advanced progressive P-NETs based on the results of an international ...